Impaired endothelium-dependent forearm vasodilation in idiopathic dilated cardiomyopathy is related to severe left ventricular dysfunction and elevated serum tumor necrosis factor levels;La disfunción endotelial periférica en la miocardiopatía dilatada idiopática se asocia con mayor disfunción ventricular y concentraciones plasmáticas elevadas de factor de necrosis tumoral

Revista Espanola de Cardiologia

Volumn 58, Issue 5, 2005, Pages 477-483

  Sitges, Marta ^a   Roig, Eulàlia ^a   Morales, Manel ^a   Azqueta, Manel ^a   Pérez Villa, Félix ^a   Paré, Carles ^a   Orús, Josefina ^a   Heras, Magda ^a   Sanz, Ginés ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Dilated cardiomyopathy; Endothelial dysfunction; Tumor necrosis factor

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; GLYCERYL TRINITRATE; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; NEUROHORMONE; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOGRAPHY; ENDOTHELIUM INJURY; FEMALE; FOREARM; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; MALE; PROTEIN BLOOD LEVEL; SYSTOLE; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 21244458776     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13074841     Document Type: Article

References (30)

1. Elkayam U, Khan S, Mehboob A, Ahsan N. Impaired endothelium-mediated vasodilatation in heart failure: clinical evidence and the potential for therapy. J Cardiac Fail. 2002;8:15-20.
2. Ferrari R, Bachetti T, Agnoletti L, Comini L, Curello S. Endothelial function and dysfunction in heart failure. Eur Heart J. 1998;19 Suppl G:41-7.
3. Drexler H. Endothelium as a therapeutic target in heart failure. Circulation. 1999;98:2652-5.
4. Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation. 1998;98:2709-15.
5. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-83.
6. Sitges M, Heras M, Roig E, Duran M, Masotti M, Zurbano MJ, et al. Acute and mid-term combined hormone replacement therapy improves endothelial function in postmenopausal women with angina and angiographically normal coronary arteries. Eur Heart J. 2001;22:2116-24.
7. Hornig B, Maier V, Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation. 1996;93:210-4.
8. Katz SD, Schwarz M, Yuen J, LeJemtel T. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation. 1993;88:55-61.
9. Kubo SH, Recto TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation. 1991;84:1589-96.
10. Katz SD, Krum H, Kahn T, Knecht M. Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium-derived nitric oxide. J Am Coll Cardiol. 1996;28:585-90.
11. Ceconi C, Curello S, Bachetti T, Corti A, Ferrari R. Tumor necrosis factor in congestive heart failure: a mechanism of disease for the new millennium? Prog Cardiovasc Dis. 1998;41 Suppl 1:25-30.
12. Satoh M, Nakamura M, Saitoh H, Maesawa CH, Segawa I, Tashiro A, et al. Tumor necrosis factor-α-converting enzyme and tumor necrosis factor-α in human dilated cardiomyopathy. Circulation. 1999;99:3260-5.
13. Herrera Garza EH, Herrera Garza JL, Rodríguez González H, Treviño Treviño A, Ibarra Flores M, Torre Amione G. Importancia del factor de necrosis tumoral alfa en la patogenia de la insuficiencia cardíaca. Rev Esp Cardiol. 2002;55:61-6.
14. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α. Circulation. 1998; 97:1375-81.
15. Densem CG, Hutchinson IV, Yonan N, Brooks NH. Tumour necrosis factor α gene polymrphism: a predisposing factor to non-ischaemic myocardial dysfunction? Heart. 2002;87:153-5.
16. Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol. 1994;266 Suppl H:2535-41.
17. Katz SD, Rao R, Berman JW, Schwarz M, Demopoulos L, Bijou R, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation. 1994;90:12-6.
18. Anker SD, Volterrani M, Egerer KR, Felton CV, Kox WJ, Poole-Wilson PA, et al. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. QJM. 1998;91:199-203
19. Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology. En: Cytokines. Philadelphia: WB Saunders Company; 1994. p. 240.
20. You Fang Z, Marwick TH. Vascular dysfunction and heart failure: epiphenomenon or etiologic agent? Am Heart J. 2002;143:383.
21. Adamopoulos S, Parissis J, Kartazas D, Kroupis C, Georgiadis M, Karavolias G, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/Soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol. 2002; 39:653-63.
22. Ohtsuka T, Hamada M, Saeki H, Ogimoto A, Hiasa G, Hara Y, et al. Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 2002;89:996-9.
23. Drexler H, Kurz S, Jeserich M, Munzel T, Hornig B. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Am J Cardiol. 1995;76:13-8.
24. Farquharson CA, Strthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction and suppresses vascular angiotensin I/ angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-7.
25. Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002;106:2184-7.
26. Fichtlscherer S, Rössig L, Breuer S, Vasa M, Dimmeler S, Zeiher AM. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation. 2001;104:3023-5.
27. Mathier MA, Rose GA, Fifer MA, Miyamoto MI, Dinsmore RE, Castaño HH, et al. Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1998;32:216-24.
28. Louis A, Cleland JG, Crabbe S, Ford S, Thackray S, Houghton T, et al. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail. 2001;3:381-7.
29. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, et al. Results targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103:1044-7.
30. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor α, in patients with moderate to severe heart failure. Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133-40.